Aeterna Zentaris Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, Nov. 25, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the closing of its\n previously announced public offering of 13.1 million units (the\n \"Offering\") generating net proceeds of approximately US$13.7 million,\n with each unit consisting of one common share and one whole warrant to\n purchase one common share, at a purchase price of US$1.15 per unit.\n Each warrant is exercisable for a period of five years at an exercise\n price of US$1.60 per share. Canaccord Genuity Inc. acted as the sole\n book-running manager, and Maxim Group LLC act as co-manager for the\n Offering.\n\n\nThe Company intends to use the net proceeds from the Offering to\n continue to fund its ongoing drug development activities, primarily for\n the advancement of its zoptarelin doxorubicin (AEZS-108) program,\n secondly for its macimorelin acetate (AEZS-130) program, including the\n preparation of its commercial launch, as well as for the potential\n addition of commercialized products to the Company's pipeline, future\n negative cash flow, general corporate purposes and working capital.\n\n\nThis press release does not and shall not constitute an offer to sell or\n the solicitation of an offer to buy any of the Company's securities,\n nor shall there be any sale of the Company's securities in any state or\n jurisdiction in which such offer, solicitation or sale would be\n unlawful prior to registration or qualification under the securities\n laws of any such state or jurisdiction. \n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a specialty biopharmaceutical company engaged in\n developing novel treatments in oncology and endocrinology. The\n Company's pipeline encompasses compounds from drug discovery to\n regulatory approval. For more information, visit www.aezsinc.com.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements made pursuant to\n the safe harbour provisions of the U.S. Securities Litigation Reform\n Act of 1995. Forward-looking statements involve known and unknown risks\n and uncertainties that could cause the Company's actual results to\n differ materially from those in the forward-looking statements. Such\n risks and uncertainties include, among others, the availability of\n funds and resources to pur...

More updates from Cosciens Biopharma Inc.